Synthesis and Evaluation of Cyclic Secondary Amine Substituted Phenyl and Benzyl Nitrofuranyl Amides As Novel Antituberculosis Agents

Overview

Journal J Med Chem

Publisher American Chemical Society

Specialty Chemistry

Date 2005 Dec 22

PMID 16366608

Citations 15

Authors

Rajendra P Tangallapally

Raghunandan Yendapally

Robin E Lee

Anne J M Lenaerts

Richard E Lee

Affiliations

Soon will be listed here.

Abstract

In an ongoing effort to develop new and potent antituberculosis agents, a second-generation series of nitrofuranyl amides was synthesized on the basis of the lead compound 5-nitrofuran-2-carboxylic acid 3,4-dimethoxybenzylamide. The primary design consideration was to improve the solubility and consequently the bioavailability of the series by the addition of hydrophilic rings to the benzyl and phenyl B ring core. The synthesis of 27 cyclic, secondary amine substituted phenyl and benzyl nitrofuranyl amides is described and their activity against Mycobacterium tuberculosis reported. The series showed a strong structure-activity relationship as the benzyl nitrofuranyl amides were significantly more active than similarly substituted phenyl nitrofuranyl amides. Para-substituted benzyl piperazines showed the most antituberculosis activity. Compounds in the series were subsequently selected for bioavailability and in vivo testing. This study led to the successful discovery of novel compounds with increased antituberculosis activity in vitro and a better understanding of the requisite pharmacological properties to advance this class.

Citing Articles

Persulfate-Promoted Carbamoylation/Cyclization of Alkenes: Synthesis of Amide-Containing Quinazolinones.

Tang J, Zhao M, Lin Y, Yang L, Xie L Molecules. 2024; 29(5).

PMID: 38474508 PMC: 10934161. DOI: 10.3390/molecules29050997.

Discovery and characterization of antimycobacterial nitro-containing compounds with distinct mechanisms of action and efficacy.

Eke I, Williams J, Haiderer E, Albrecht V, Murdoch H, Abdalla B Antimicrob Agents Chemother. 2023; 67(9):e0047423.

PMID: 37610224 PMC: 10508139. DOI: 10.1128/aac.00474-23.

Metal-Free Synthesis of Carbamoylated Chroman-4-Ones via Cascade Radical Annulation of 2-(Allyloxy)arylaldehydes with Oxamic Acids.

Xie L, Peng S, Yang L, Liu X Molecules. 2022; 27(20).

PMID: 36296640 PMC: 9609457. DOI: 10.3390/molecules27207049.

Optimization of N-benzyl-5-nitrofuran-2-carboxamide as an antitubercular agent.

Gallardo-Macias R, Kumar P, Jaskowski M, Richmann T, Shrestha R, Russo R Bioorg Med Chem Lett. 2019; 29(4):601-606.

PMID: 30600207 PMC: 6368976. DOI: 10.1016/j.bmcl.2018.12.053.

A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters.

Nikiforov P, Surade S, Blaszczyk M, Delorme V, Brodin P, Baulard A Org Biomol Chem. 2016; 14(7):2318-26.

PMID: 26806381 PMC: 4759522. DOI: 10.1039/c5ob02630j.

References

Barry 3rd C, Boshoff H, Dowd C . Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis. Curr Pharm Des. 2004; 10(26):3239-62. DOI: 10.2174/1381612043383214. View

Gruppo V, Johnson C, Marietta K, Scherman H, Zink E, Crick D . Rapid microbiologic and pharmacologic evaluation of experimental compounds against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2006; 50(4):1245-50. PMC: 1426968. DOI: 10.1128/AAC.50.4.1245-1250.2006. View

Domagala J, Hanna L, Heifetz C, Hutt M, Mich T, Sanchez J . New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay. J Med Chem. 1986; 29(3):394-404. DOI: 10.1021/jm00153a015. View

Kelly B, Furney S, Jessen M, Orme I . Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1996; 40(12):2809-12. PMC: 163627. DOI: 10.1128/AAC.40.12.2809. View

Tangallapally R, Yendapally R, Lee R, Hevener K, Jones V, Lenaerts A . Synthesis and evaluation of nitrofuranylamides as novel antituberculosis agents. J Med Chem. 2004; 47(21):5276-83. DOI: 10.1021/jm049972y. View

Dye C, Scheele S, Dolin P, Pathania V, Raviglione M . Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA. 1999; 282(7):677-86. DOI: 10.1001/jama.282.7.677. View

Orme I . Search for new drugs for treatment of tuberculosis. Antimicrob Agents Chemother. 2001; 45(7):1943-6. PMC: 90582. DOI: 10.1128/AAC.45.7.1943-1946.2001. View

Tokuyama R, Takahashi Y, Tomita Y, Tsubouchi M, Yoshida T, Iwasaki N . Structure-activity relationship (SAR) studies on oxazolidinone antibacterial agents. 2. Relationship between lipophilicity and antibacterial activity in 5-thiocarbonyl oxazolidinones. Chem Pharm Bull (Tokyo). 2001; 49(4):353-60. DOI: 10.1248/cpb.49.353. View

SENSI P, Maggi N, FURESZ S, Maffii G . Chemical modifications and biological properties of rifamycins. Antimicrob Agents Chemother (Bethesda). 1966; 6:699-714. View

10.

Lenaerts A, Gruppo V, Brooks J, Orme I . Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice. Antimicrob Agents Chemother. 2003; 47(2):783-5. PMC: 151769. DOI: 10.1128/AAC.47.2.783-785.2003. View

11.

Takahashi H, Chida Y, Yoshii T, Suzuki T, YANAURA S . Asymmetric alpha-substituted phenethylamines. VI. Synthesis and analgesic activity of optically pure (R)- and (S)-N-alkyl-1-cyclohexyl-2-phenylethylamines. Chem Pharm Bull (Tokyo). 1986; 34(5):2071-7. DOI: 10.1248/cpb.34.2071. View

12.

Lee R, Protopopova M, Crooks E, Slayden R, Terrot M, Barry 3rd C . Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. J Comb Chem. 2003; 5(2):172-87. DOI: 10.1021/cc020071p. View

13.

de Jong B, Israelski D, Corbett E, Small P . Clinical management of tuberculosis in the context of HIV infection. Annu Rev Med. 2004; 55:283-301. DOI: 10.1146/annurev.med.55.091902.103753. View